Showing posts with label Brussels Regulation. Show all posts
Showing posts with label Brussels Regulation. Show all posts

Monday, February 23, 2026

Judge Albright’s Order in BMW v. Onesta

As noted on this blog previously (see here and here), in December Judge Alan Albright (W.D. Tex.) issued a temporary restraining order, later converted into a preliminary injunction, ordering U.S. patent assertion entity Onesta from adjudicating claims against BMW for the infringement of U.S. patents in the Munich Regional Court.  On February 13, the judge issued his written order explaining his reasoning.  The order is available on Westlaw (2026 WL 474871) and from other sources, such as Pacer.

By way of background, one year ago the Court of Justice for the European Union issued its decision in BSH v. Electrolux.  In that case, the owner of a European Patent filed an action in Sweden, against a defendant domiciled in Sweden, for the infringement not only of the Swedish part of the patent in suit, but also for the infringement of the corresponding parts validated in nine other European Patent Convention (EPC) member states--including at least one (Türkiye) which is not an EU member.  One of the questions presented was whether the Brussels Regulation Recast conferred exclusive jurisdiction over a Turkish court in respect of the part validated in Turkey.  The court held that it did not, but rather that the Swedish court may adjudicate both the infringement and validity of the Turkish part, although the validity ruling would apply only inter partes (in other words, the effect of the ruling would not be to nullify the Turkish part as against the world).  In reaching this conclusion, the court stated that

. . . the court of the Member State in which the defendant is domiciled which is seised, as in the case in the main proceedings, on the basis of Article 4(1) of the Brussels I bis Regulation, of an infringement action in the context of which the issue of the validity of a patent granted or validated in a third State is raised as a defence, does have jurisdiction to rule on that issue if none of the restrictions referred to in paragraphs 63 to 65 of the present judgment is applicable, given that the decision of that court sought in that regard is not such as to affect the existence or content of that patent in that third State, or to cause its national register to be amended.

 

. . . As the Advocate General observed in point 62 of his Opinion of 22 February 2024 and as the parties to the main proceedings and the European Commission stated at the hearing on 14 May 2024 before the Court, that decision has only inter partes effects, that is to say, a scope limited to the parties to the proceedings. Thus, where the issue of the validity of a patent granted in a third State is raised as a defence in an action alleging infringement of that patent before a court of a Member State, that defence seeks only to have that action dismissed, and does not seek to obtain a decision that will cause that patent to be annulled entirely or in part. In particular, under no circumstances can that decision include a direction to the administrative authority responsible for maintaining the national register of the third State concerned (paras. 74-75).

The court’s reasoning does not, at least explicitly, appear to hinge on the “third State” being a party to the EPC, and thus could be cited in support of the Munich court’s jurisdiction to adjudicate claims for the infringement of a U.S. patent in an action filed against a company (like BMW) domiciled in Germany.  Then again, as Judge Albright notes in his order, the BSH “decision never expressly grants long-arm authority to divest U.S. courts of jurisdiction to enforce U.S. patents.”  Fair enough.

In any event, in granting the ASI, Judge Albright goes through the Fifth Circuit’s test for granting an ASI, which is largely similar to what other U.S. circuits require.  First, it is undisputed that the parties to the U.S. and Munich actions are the same, and the U.S. action (BMW’s action for a declaratory judgment of patent misuse, noninfringement, and invalidity) would dispose of the relevant issues in Munich.  Second, the Munich action would “frustrate a policy of the forum issuing the injunction” or, alternatively, would “cause prejudice or offend other equitable principles.”  In this regard, he writes that “[a]llowing the Munich proceedings to continue threatens the United States' policy interest in adjudicating its own patents and protecting litigants' jury rights in infringement cases. Similarly, proceedings in the Munich court necessarily deprive BMW of critical defendant rights available only here—e.g., fact discovery; invalidity consideration with erga omnes effect; and juries as a bulwark against the improper grant or assertion of U.S. patents. . . .  [E]nsuring that U.S. patent infringement claims are adjudicated in U.S. courts is ‘necessary to provide full justice to the parties’ in this case because BMW seeks a jury trial on the infringement claims” (citation omitted).  Further, in Judge Albright’s reading, the Paris Convention “expressly affirms the independence of each country’s patent system and reserves the ‘provisions . . . relating to . . .  jurisdiction’ to each member state” (quoting Voda v. Cordis Corp., 476 F.3d 887, 898-99 (Fed. Cir. 2007)).  In addition, although there is case law authorizing the adjudication of U.S. copyright claims in foreign courts (and, I would note, vice versa), the court notes that “[u]nlike with copyrights, receiving patent protections in the U.S. requires a rigorous application and examination process”; and he cites the act of state doctrine, which in general counsels against second-guessing the exercise of another state’s sovereign authority.  Third, the court finds that an ASI would not offend international comity because “comity is implicated by ‘public international issues,’ but not ‘private’ disputes” (though one might ask, if that is the case, why courts should bother considering comity at all in the context of deciding whether to grant an ASI in a private dispute).  He does note, however, that

 

There are factors present in this case that are abnormal in the ASI context. For instance, the Court is unaware of any cases where an ASI has been granted to terminate the first filed proceedings between the parties. Moreover, this case features the unusual argument by Onesta that BMW would be inconvenienced by defending in a forum outside of its domicile, while BMW seeks courts outside its domicile. . . . But there is no recognized first-filed principle. See Laker Airways Ltd. v. Sabena, Belgian World Airlines, 731 F.2d 909, 927 (D.C. Cir. 1984) (“The mere filing of a suit in one forum does not cut off the preexisting right of an independent forum to regulate matters subject to its prescriptive jurisdiction.”); Microsoft Corp. v. Motorola, Inc., 696 F.3d 872, 887 (9th Cir. 2012) (“The order in which the domestic and foreign suits were filed ... [is] not dispositive.”). And making sure that U.S. patents are tried in U.S. courts, which regularly apply U.S. patent law is more “convenien[t]” for the courts of each sovereign. . . .Finally, given Onesta's domicile in the United States and BMW's desire to litigate here, the Court finds that neither party would be inconvenienced by doing so. . . .

It will be interesting to see what happens on appeal if the parties do not settle the matter or at least agree to some procedure for resolving it--though I suspect that under U.S. law it may be difficult to overturn the decision on appeal.  Nevertheless, here are a few random thoughts:

1.     The court invokes the United States’ interest in adjudicating its own patents and protecting litigants’ rights to a jury trial, to fact discovery, and to an invalidity determination with erga omnes effect.  But of course all of those things would be unavailable in a case in which a foreign court adjudicates foreign copyright rights, about which the court is more sanguine.  And is it really true that the adjudication of U.S. patent infringement claims in a U.S. court is “necessary to provide full justice to the parties” because BMW seeks a jury trial?  To my knowledge, no other country in the world provides jury trials in patent infringement actions (or discovery to the same extent the U.S. does, for that matter); does that mean that every country’s system is unjust?  I suppose the response would be no, it’s just that actions for the infringement of U.S. patent rights come with a guarantee of right to trial by jury, as a matter of U.S. constitutional law (and regardless of whether the party requesting a jury is the plaintiff or the defendant, domestic or foreign), and therefore the Munich court’s inability to convene a jury would render its decision on U.S. patent infringement claims unjust.  But again, if that is true, why isn’t it true for copyright claims—or other instances in which foreign courts might make determinations under U.S. law?

2.  A more serious problem, in my view, is that in countries such as Germany infringement and validity determinations are bifurcated—determined by different courts in different proceedings—such that a judgment of infringement may be entered with regard to a patent later determined to be invalid (the “injunction gap”).  Moreover, injunctive relief in favor of the prevailing patentee is near-automatic, indeed often viewed as being part of the claim for relief, rather than merely a remedy as in Anglo-American law.  See my new book, p.10 n.23 (stating that “in common law systems the law of remedies is viewed as something of a stand-alone discipline, albeit one that may be applied in different ways in relation to different bodies of private law.  In civil law countries such as Germany, by contrast, rights and remedies are viewed as being more closely connected, such that, as indicated in the text above, the infringement of a patent (for example) almost always results in the entry of an injunction. See Franz Hofmann and Franziska Kurz, Introduction to the “Law of Remedies,” in Law of Remedies: A European Perspective 3, 5 (Franz Hofmann and Franziska Kurz eds., Intersentia Ltd. 2019) (stating that “[u]nlike in common law countries, the question is not: which remedies are available to cure a wrong? Instead, German lawyers comprehend the legal system as a compilation of ‘subjective rights’”).”  So if a German court were to decide the infringement action against BMW, would it have to depart from its standard practice and consider whether the U.S. patent is valid?  Would the availability of an injunction be determined under German or under U.S. (eBay) law?  Beats me—but I can see why BMW, despite not being “inconvenienced” by litigating in its home forum, might prefer to take its chances in Texas, despite the possible risk of a larger damages award under U.S. law, if the case were to proceed that far.

3.  As many readers know, German courts generally disapprove of other states granting ASIs directed against the litigation of disputes or the enforcement of judgments in German courts.  That perspective may not matter so much here, however, if the German court itself would prefer not to have to decide some of the questions above, or if it would be inclined in any event to stay the adjudication of the U.S. patents pending proceedings in the U.S. (something the CJEU expressly suggested as a possibility in a case in which an E.U. court is asked to adjudicate a claim arising under another E.U. member state’s law).  But let’s imagine, just for the sake of argument, a case in which an E.U. court was asked to adjudicate a claim for the infringement of a U.S. patent and was not willing to cede jurisdiction to the U.S. court that enjoins the E.U. plaintiff from proceeding in the E.U.; maybe the E.U. court issues an AASI in response.  Which country is violating the comity norm:  the country issuing the ASI (which, one could agree, indirectly interferes with the operation of a foreign court), or the court that claims the right to adjudicate foreign patent claims (which, one could argue, indirectly interferes with the operation of its counterpart)?  Note that the WTO arbitration award last summer in the dispute between the EU and China can be read as disapproving both of ASIs (that is, disapproving of them beyond the context of the Chinese ASI policy at issue) and of the adjudication of foreign IP rights.  See my post on the WTO decision here, points 6b and 6c.  Then again, what precedential value, if any, does a WTO arbitration award have?

4.  There is some non-binding authority under U.S. law that might disagree with the position staked out by Judge Albright in BMW.  For example, section 211 of the American Law Institute’s 2007 Principles of the Law—Intellectual Property, titled “Subject-Matter Jurisdiction over Claims,” recommends that, in general, “a court is competent to adjudicate claims arising under foreign laws pertaining to the subject matter of these Principles,” as long as it has subject matter and personal matter jurisdiction under local law, and as long as “[a] judgment holding registered rights granted under the laws of another State invalid is effective only to resolve the dispute between or among the parties to the action.”  Similarly, in her dissent in Voda v. Cordis, 476 F.3d 887 (Fed. Cir. 2007), Judge Pauline Newman disputed, among other things, the characterization of patent grants as “acts of state” (as opposed to ministerial acts) for purposes of the act of state doctrine, and also did not believe that the Paris Convention or TRIPS Agreement “prohibits resolution by a national court of private disputes that include foreign patent rights.  She wrote:

The panel majority raises the specter that foreign courts might adjudicate United States patent rights, proposing that if our courts are permitted to decide questions under foreign patent law, other countries will feel free to decide questions of United States patent law. Cordis too sounds the alarm, stating that creative litigants will choose exotic foreign forums to resolve complex patent issues, and that the district court's decision will open the door to international chaos. I doubt that a United States district court is an exotic foreign forum; and it is not new for courts in other countries to apply the law of other nations when warranted. . . . All nations have recognized their obligation to provide a judicial forum to address disputes involving their citizens; no warrant has been shown to remove foreign patents from this purview.

Judge Newman’s dissent did not expressly grapple with Paris Convention articles 2(3) and 4bis, however, though perhaps an argument could be made that neither provision necessarily or inherently entails exclusive adjudicatory jurisdiction.  Whether that is the correct reading of the Convention, I’m not sure.  

Tuesday, February 25, 2025

CJEU Delivers Decision on Extraterritorial Jurisdiction

Earlier today, the Court of Justice for the European Union issued its decision in BSH Haugeräte GmbH v. Electrolux AB, Case C‑339/22.  As I noted in my April 2024 blog post, published after the CJEU decided that a Grand Chamber would rehear the matter, BSH owned EP 1 434 512, which was validated in ten EPO member states, including non-EU members Türkiye and the U.K.  In 2020, BSH filed an infringement action against Electrolux in Sweden, where Electrolux is domiciled, alleging the infringement of all ten of these national patents.  The patents have since expired, but BSH still hopes to recover damages.  In its defense, Electrolux argued that, because Electrolux has raised invalidity as a defense, article 24(4) of the Brussels I bis Regulation (Regulation (EU) No 1215/2012 of the European Parliament and of the Council of 12 December 2012 on jurisdiction and the recognition and enforcement of judgments in civil and commercial matters) and CJEU case law (specifically, GAT v. LuK, Case C-4/03 (2006) and Roche Nederland BV v. Primus, Case C-539/03 (2006)), constrain the Swedish court to adjudicate only the alleged infringement of the Swedish patent; and that the question of whether the defendant has infringed the other national patents can be decided only in each of the ten patent-validating nations, even if invalidity is raised only as a defense. 

Of particular relevance here are article 4(1) of the Regulation, which states that “Subject to this Regulation, persons domiciled in a Member State shall, whatever their nationality, be sued in the courts of that Member State,” and the aforementioned article 24(4), reads as follows:

 

The following courts of a Member State shall have exclusive jurisdiction, regardless of the domicile of the parties:

 

           

(4)      in proceedings concerned with the registration or validity of patents …, irrespective of whether the issue is raised by way of an action or as a defence, the courts of the Member State in which the deposit or registration has been applied for [or] has taken place …

 

Without prejudice to the jurisdiction of the European Patent Office under [the EPC], the courts of each Member State shall have exclusive jurisdiction in proceedings concerned with the registration or validity of any European patent granted for that Member State.

The questions referred to the CJEU were the following:

1. Is Article 24(4) of Regulation (EU) 1215/2012 1 of the European Parliament and of the Council of 12 December 2012 on jurisdiction and the recognition and enforcement of judgments in civil and commercial matters to be interpreted as meaning that the expression ‘proceedings concerned with the registration or validity of patents … irrespective of whether the issue is raised by way of an action or as a defence’ implies that a national court, which, pursuant to Article 4(1) of that regulation, has declared that it has jurisdiction to hear a patent infringement dispute, no longer has jurisdiction to consider the issue of infringement if a defence is raised that alleges that the patent at issue is invalid, or is the provision to be interpreted as meaning that the national court only lacks jurisdiction to hear the defence of invalidity?

 

2. Is the answer to Question 1 affected by whether national law contains provisions, similar to those laid down in the second subparagraph of Paragraph 61 of the Patentlagen (Patents Law), which means that, for a defence of invalidity raised in an infringement case to be heard, the defendant must bring a separate action for a declaration of invalidity?

 

3. Is Article 24(4) of the Brussels I Regulation 1 to be interpreted as being applicable to a court of a third country, that is to say, in the present case, as also conferring exclusive jurisdiction on a court in Türkiye in respect of the part of the European patent which has been validated there?

In its decision today, the Court concludes, with respect to questions 1 and 2, that under article 24(4) “the courts of each [EU] Member States are to have exclusive jurisdiction in proceedings concerned with the registration or validity of any European patent granted for that Member State” (para. 32).  However, “the exclusive jurisdiction rule laid down in Article 24(4) of the Brussels I bis Regulation concerns only the part of the dispute relating to the validity of the patent. Accordingly, a court of the Member State in which the defendant is domiciled, which has jurisdiction, under Article 4(1) of the Brussels I bis Regulation, in an action alleging infringement of a patent granted in another Member State, does not lose that jurisdiction merely because, as its defence, that defendant challenges the validity of that patent” (para. 41).  That said, if the court in which the infringement action is pending “considers it justified, in particular where it takes the view that there is a reasonable, non-negligible possibility of that patent being declared invalid by the court of that other Member State that has jurisdiction . . . the court seised of the infringement action may, where appropriate, stay the proceedings, which allows it to take account, for the purpose of ruling on the infringement action, of a decision given by the court seised of the action seeking a declaration of invalidity” (para. 51). 

With respect to the third question, however, involving patents issued by non-EU Member States, we get a different result, unless the third country is a member of the Lugano Convention, which has a provision similar to article 24(4), or there is a bilateral convention in place stipulating that “the courts of that third State are to have exclusive jurisdiction over disputes relating to the validity of patents granted in that third State” (para. 64).  (The non-E.U. members of the Lugano Convention are Iceland, Norway, and Switzerland.)  A court of an E.U. Member States also may, under some circumstances, stay proceedings if there are proceedings “already pending before a court of a third State” (para. 65).  Here, however, it appears that “Türkiye is not a State that is party to the Lugano Convention and the file before the Court contains no indication as to whether there is an applicable convention between the Kingdom of Sweden and that third State or as to whether there are proceedings pending before a court of that third State, within the meaning of Articles 33 and 34 of the Brussels I bis Regulation” (para. 66).  The Court then considers whether, if as here none of the above conditions apply, general international law would pose an obstacle to an E.U. Member State court evaluating the validity of a patent issued by a third country.  The Court concludes that, because such issuance “is an exercise of national sovereignty,” a court of an E.U. Member States cannot nullify such a patent, but it may decide the question of validity as long as that decision applies only inter partes—that is, it doesn’t cancel the foreign patent as against everyone, but only finds the patent invalid as between the plaintiff and the defendant in the specific case before the court (para. 75).

So, consider the following example.  Patentee P, domiciled in Germany, owns corresponding patents in Germany, France, and the United States.  P sues defendant D in France, where D is domiciled.  D argues, in its defense, that all three national patents are invalid under the laws of the issuing country.  If I understand correctly, the French court may adjudicate the infringement of all three patents.  It also may determine, in accordance with French law, whether the claims in suit of the French patent are valid or invalid—and if it decides they are invalid, then that decision will apply erga omnes (against the world), because that is the effect of such a determination in France.  On the other hand, the French court may not adjudicate, even indirectly, the validity of the German patent, though it has discretion to stay the infringement action with respect to the German patent pending an invalidation action in Germany.  Finally, the French court may adjudicate the infringement of the U.S. patent, and it may determine whether the claims in suit are valid—though if it decides they are invalid, that decision will apply only inter partes; and as Florian Mueller suggests it probably could instead stay the action under its own domestic law. But even if it does conclude the U.S. claims are invalid, the U.S. patent would still be presumed valid as against the rest of the world.

Some questions to consider are the following.  First, in the above example, would the French court decide the remedies for the infringement of the German and U.S. patents in accordance with, respectively, German and U.S. law, or in accordance with French law?  That may depend on whether French law considers remedies to be procedural or substantive, which is something I may research in the coming days.  I am inclined to think that they should be considered substantive, and therefore determined by the law of the state of registration, but that may not be the universally-held view.  (For discussion, see, e.g., my article Extraterritorial Damages in Copyright Law, 74 Fla. L. Rev. 123, 163 n.204 (2022) (citing various sources).  Second, would the Unified Patent Court, as opposed to the French domestic court in the above hypothetical, be able to decide the infringement of non-EPO patents?  It would appear not, under UPCA arts. 2, 32, which limits the court’s jurisdiction to EPO-granted patents and to SPCs; but after BSH, it could decide infringement and award remedies for the infringement of EPO-granted patents even in non-UPC countries such as the U.K., or countries such as Ireland that have signed but not yet ratified the UPCA.  (In fact, that would be consistent with a recent UPC decision, Fujifilm Corp. v. Kodak GmbH, UPC_CFI_355/2023 (Düsseldorf Local Division 2025), that predates BSH.)  Third, in the above example, would a U.S. court enforce a judgment rendered by the French court against the defendant’s U.S. assets?  Presumably yes, unless there were some credible argument that the French decision was against U.S. public policy.  Fourth, will U.S. courts rethink their view, as expressed in Voda v. Cordis Corp., 476 F.3d 887 (Fed. Cir. 2007), that they lack subject matter jurisdiction to adjudicate the infringement of foreign patents, even when invalidity is not at issue?   Time will tell.

Thursday, April 18, 2024

CJEU Grand Chamber to Hear Argument Concerning Cross-Border Relief

Last week, Florian Mueller published a post on his new site ipfray, titled Grand Chamber of European Court of Justice takes patent case—question of cross-border jurisdiction.  The case at issue is BSH Haugeräte GmbH v. Electrolux AB, and although the questions referred date back to May 2022 and the case has already been heard by a regular chamber, the CJEU’s decision to assign the matter to a “Grand Chamber” of fifteen judges is recent. The questions referred are:

Is Article 24(4) of Regulation (EU) 1215/2012 1 of the European Parliament and of the Council of 12 December 2012 on jurisdiction and the recognition and enforcement of judgments in civil and commercial matters to be interpreted as meaning that the expression ‘proceedings concerned with the registration or validity of patents … irrespective of whether the issue is raised by way of an action or as a defence’ implies that a national court, which, pursuant to Article 4(1) of that regulation, has declared that it has jurisdiction to hear a patent infringement dispute, no longer has jurisdiction to consider the issue of infringement if a defence is raised that alleges that the patent at issue is invalid, or is the provision to be interpreted as meaning that the national court only lacks jurisdiction to hear the defence of invalidity?

 

Is the answer to Question 1 affected by whether national law contains provisions, similar to those laid down in the second subparagraph of Paragraph 61 of the Patentlagen (Patents Law), which means that, for a defence of invalidity raised in an infringement case to be heard, the defendant must bring a separate action for a declaration of invalidity?

 

Is Article 24(4) of the Brussels I Regulation 1 to be interpreted as being applicable to a court of a third country, that is to say, in the present case, as also conferring exclusive jurisdiction on a court in Turkey in respect of the part of the European patent which has been validated there?

The basic facts are these.  BSH owned EP 1 434 512, validated in ten EPO member states, including Türkiye and the U.K.  In 2020, BSH filed an infringement action against Electrolux in Sweden, for infringing all ten national patents.  The patents have since expired, but BSH still hopes to recover damages.  Electrolux argues, however, that because Electrolux raises invalidity as a defense, article 24(4) of the Brussels I bis Regulation (Regulation (EU) No 1215/2012 of the European Parliament and of the Council of 12 December 2012 on jurisdiction and the recognition and enforcement of judgments in civil and commercial matters) and CJEU case law (specifically, GAT v. LuK, Case C-4/03 (2006) and Roche Nederland BV v. Primus, Case C-539/03 (2006)), constrain the Swedish court to adjudicate only the alleged infringement of the Swedish patent; and that the question of whether the defendant has infringed the other national patents can be decided only in those patent-validating nations, even if invalidity is raised only as a defense.  Article 24(4), which was added to the Regulation to conform to the decision in GAT v. LuK, reads as follows (with ellipses as in AG Emiliou's opinion, discussed below):

 

The following courts of a Member State shall have exclusive jurisdiction, regardless of the domicile of the parties:

 

           

(4)      in proceedings concerned with the registration or validity of patents …, irrespective of whether the issue is raised by way of an action or as a defence, the courts of the Member State in which the deposit or registration has been applied for [or] has taken place …

 

Without prejudice to the jurisdiction of the European Patent Office under [the EPC], the courts of each Member State shall have exclusive jurisdiction in proceedings concerned with the registration or validity of any European patent granted for that Member State.

For its part, BSH urges that the Swedish court should consider the infringement of all ten patents, though if Electrolux contests validity, the court may provisionally stay any judgment of infringement until invalidation proceedings brought in the patent-validating countries are final. 

Interestingly, the Advocate General’s opinion strongly criticizes GAT v. LuK but recognizes that because the rule the court articulated in that case is now codified as article 24(4), there is no question of the court overruling it.  Instead, he argues that the “lesser evil” is, essentially, that urged by BSH, namely that the Swedish court (the court of the defendant’s domicile) has jurisdiction over the infringement claims, but should consider staying proceedings pending the outcome of invalidation actions in the other countries.  As for Türkiye, which is not bound by Brussels Regulation bis I (as the U.K. is, even after Brexit, as a matter of domestic legislation), EU law cannot confer upon the Turkish court exclusive jurisdiction over matters related to patent validity.  Nevertheless, while the court of an EU member state such as Sweden may have jurisdiction to decide the validity of the Turkish patent (without an erga omnes effect), the AG recommends that it may decline to exercise that jurisdiction “reflexively” (that is, to treat the matter as it would if the other state were an EU member state, subject to "some limited discertion" (para. 152)).      

For further analysis, see posts by Geert van Calster and by Lydia Lundstedt.  For background on GAT v. LuK, Roche v. Primus, and other relevant CJEU case law, see Paul England, Cross-border actions in the CJEU and English Patents Court--ten years on from GAT v. LuK, 12 JIPLP 105 (2017); see also my book pp. 250-53.